Applied Therapeutics Announces Appointment of Dr. Chuck Silberstein, MD, MBA, CFA as Chief Financial Officer and Head of Busi...
26 Maggio 2020 - 1:00PM
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage
biopharmaceutical company developing a pipeline of novel drug
candidates against validated molecular targets in indications of
high unmet medical need, announced today the appointment of
Dr. Charles (Chuck) Silberstein, MD, MBA, CFA as Chief Financial
Officer and Head of Business Development, effective
immediately. Dr. Silberstein is replacing Dr. Mark Vignola,
who will be moving on to pursue new business
opportunities.
“We are thrilled to have Chuck joining the
management team at Applied as we embark on this exciting phase of
commercialization and program expansion,” said Dr. Shoshana
Shendelman PhD, Founder, CEO and Chair of the Board. “His
experience across all aspects of the business, including corporate
strategy and business development, solidifies our capabilities as
we move forward. We thank Dr. Mark Vignola for his contributions as
CFO in the critical year following our IPO and wish him well in his
future endeavors.”
Dr. Silberstein was formerly Senior Vice
President of Corporate Business Development at Allergan plc
(recently acquired by AbbVie). Along with broad corporate
strategy and business development skills, Dr. Silberstein brings
more than 20 years of investment and capital markets experience to
Applied, as a portfolio manager and equity healthcare analyst at
The Boston Company Asset Management and Goldman Sachs Asset
Management and as a senior healthcare equity analyst at JP Morgan
Asset Management. Dr. Silberstein received his MD from Albert
Einstein College of Medicine and his MBA from Columbia Business
School.
About Applied Therapeutics Inc.
Applied Therapeutics is a clinical-stage
biopharmaceutical company developing a pipeline of novel drug
candidates against validated molecular targets in indications of
high unmet medical need. The Company’s lead drug candidate,
AT-007, is a novel central nervous system penetrant aldose
reductase inhibitor (ARI) for the treatment of Galactosemia, a rare
pediatric metabolic disease. The Company initiated a pivotal Phase
1/2 clinical trial in June 2019, read out positive top-line
biomarker data in adult Galactosemia patients in January
2020 and announced full data from the trial in April
2020. The Company is also developing AT-001, a novel potent ARI
that is being developed for the treatment of Diabetic
Cardiomyopathy, or DbCM, a fatal fibrosis of the heart. The Company
initiated a Phase 3 registrational study in DbCM in September 2019.
The preclinical pipeline also includes AT-003, an ARI designed to
cross through the back of the eye when dosed orally, for the
treatment of diabetic retinopathy, as well as novel dual PI3k
inhibitors in preclinical development for orphan oncology
indications.
Investors: Maeve Conneighton
(212) 600-1902 or appliedtherapeutics@argotpartners.com
Media:Gleb
Sagitovmedia@appliedtherapeutics.com
Grafico Azioni Applied Therapeutics (NASDAQ:APLT)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Applied Therapeutics (NASDAQ:APLT)
Storico
Da Lug 2023 a Lug 2024